May 19th 2024
Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Roundtable Discussion: Bodor Reviews Benefits, Challenges of Immunotherapy for Squamous NSCLC
April 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced squamous non–small cell lung cancer.
Read More
Part A of THIO-101 Trial Shows Positive Topline Safety Data in NSCLC
April 12th 2023Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.
Read More
Roundtable Discussion: Kim Reviews the Use of Chemoradiation and Immunotherapy in NSCLC
April 6th 2023During a Targeted Oncology™ Case-Based Roundtable™, Edward S. Kim, MD, MBA, discussed with participants utilizing chemoradiation and immunotherapy for patients with non–small cell lung cancer.
Read More
Link Between Medicaid and Rates of Biomarker Testing in NSCLC
March 31st 2023Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.
Watch
In Second-Line, Atezolizumab/Cabozantinib Shows No Benefit Over SOC in NSCLC
March 31st 2023At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.
Read More
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC
March 20th 2023The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Read More